RIPK3 and liver disorder: Since data indicate that RIP3 can be activated independently of RIP1, development of specific pharmacological inhibitors of RIP3 will likely be necessary in some conditions to interrupt the pathophysiological impact of RIP3 in progression of liver diseases.